Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million G...
SHANGHAI, March 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO serv...
SHANGHAI, March 1, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO servi...
SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department...
* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier ...
* Enhances drug product services for projects at various stages, with an emphasis on late and com...
- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspect...
* Successfully completed 12 regulatory inspections so far this year WUXI, China, Sept. 1, 2021 /P...
* Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million * Gross Profit Grows by 191.7% Y-o-Y t...
SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company...
* First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class ...
WUXI, China and DAEJEON, South Korea, June 10, 2021 /PRNewswire/ -- WuXi XDC ("XDC"), a global CDMO...
SHANGHAI and ROCKVILLE, Md., May 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a ...
WUXI, China, May 14, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company w...
SHANGHAI, May 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with ...
SHANGHAI, April 13, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company wi...
WUXI, China, April 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company ...
Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Mi...
SUZHOU, China, March 18, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global compa...
HANGZHOU, China, March 17, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global com...